Experienced in Grass Allergy

Dr. David J. De La Zerda

Pulmonary Medicine | Hospital Medicine | Intensive Care Medicine
University Of Miami
1611 Nw 12 Th Ave, Jackson Memorial Hospital, 
Miami, FL 
Accepting New Patients
Experienced in Grass Allergy
University Of Miami
1611 Nw 12 Th Ave, Jackson Memorial Hospital, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David De La Zerda is a Pulmonary Medicine specialist and a Hospital Medicine provider in Miami, Florida. Dr. De La Zerda is rated as an Experienced provider by MediFind in the treatment of Grass Allergy. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Cerebral Hypoxia, Interstitial Lung Disease, and Gastrostomy. Dr. De La Zerda is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Hospital Medicine
Intensive Care Medicine
Licenses
Hospitalist in FL
Hospital Affiliations
Jackson Health System
Languages Spoken
English
Hebrew
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

UNIVERSITY OF MIAMI
1611 Nw 12 Th Ave, Jackson Memorial Hospital, Miami, FL 33136
Other Locations
UNIVERSITY OF MIAMI
1601 Nw 12th Ave, Miami, FL 33136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
Enrollment Status: Terminated
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell (hMSC) Infusion in Patients With Non-Cystic Fibrosis Bronchiectasis
A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell (hMSC) Infusion in Patients With Non-Cystic Fibrosis Bronchiectasis
Enrollment Status: Completed
Publish Date: August 28, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 4 Less Clinical Trials

5 Total Publications

The Cross-Regulation Between Set1, Clr4, and Lsd1/2 in Schizosaccharomyces pombe.
The Cross-Regulation Between Set1, Clr4, and Lsd1/2 in Schizosaccharomyces pombe.
Journal: PLoS genetics
Published: August 10, 2023
Similar Doctors
Distinguished in Grass Allergy
Dr. Frank Sorhage
Pulmonary Medicine
Distinguished in Grass Allergy
Dr. Frank Sorhage
Pulmonary Medicine
4851 Ne 26th Ave, 
Ft Lauderdale, FL 
 (28.1 miles away)
954-655-4922
Languages Spoken:
English, French, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Frank Sorhage is a Pulmonary Medicine provider in Ft Lauderdale, Florida. Dr. Sorhage is rated as a Distinguished provider by MediFind in the treatment of Grass Allergy. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Asthma in Children, Gastrostomy, and Endoscopy. Dr. Sorhage is currently accepting new patients.

Distinguished in Grass Allergy
Dr. Ronald J. Scott
Pulmonary Medicine
Distinguished in Grass Allergy
Dr. Ronald J. Scott
Pulmonary Medicine

Holy Cross Hospital Inc

4725 N Federal Hwy, Holy Cross Medical Group, 
Ft Lauderdale, FL 
 (27.9 miles away)
954-771-8000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronald Scott is a Pulmonary Medicine provider in Ft Lauderdale, Florida. Dr. Scott is rated as a Distinguished provider by MediFind in the treatment of Grass Allergy. His top areas of expertise are Lung Metastases, Pneumonia, Chronic Obstructive Pulmonary Disease (COPD), Gastrostomy, and Aortic Valve Replacement. Dr. Scott is currently accepting new patients.

Advanced in Grass Allergy
Dr. Nikhil Bhardwaj
Pulmonary Medicine | Intensive Care Medicine
Advanced in Grass Allergy
Dr. Nikhil Bhardwaj
Pulmonary Medicine | Intensive Care Medicine

Nikhil Bhardwaj MD PA

21355 E Dixie Hwy, Suite 102, 
Aventura, FL 
 (13.2 miles away)
305-932-2552
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Nikhil Bhardwaj is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Aventura, Florida. Dr. Bhardwaj is rated as an Advanced provider by MediFind in the treatment of Grass Allergy. His top areas of expertise are COVID-19, Asthma in Children, Asthma, Gastrostomy, and Endoscopy. Dr. Bhardwaj is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. De La Zerda's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile